Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health CVD Risk Assessment Policy Update | O…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedOscar HealthPolicy N/A

    Cardiovascular Disease Risk Assessment

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, frequency, and limitations for laboratory testing and biomarkers used to assess cardiovascular disease (CVD) risk for Oscar Health members, and indicates who and when testing is covered.

    Policy Summary
    PayerOscar Health
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy N/A
    Change TypeGuideline-driven substantive updates (SCORE2, CAC, Lp(a), LDL-C thresholds)
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefits before ordering tests and follow guideline-based indications for lipid panels, one-time Lp(a) measurement, and LDL-C–guided therapy decisions.
    SourceLink
    POLICY UPDATE CHANGES

    SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, diabetes, CKD, or genetic/rare lipid or blood pressure disorders for estimation of 10-year fatal and non-fatal CVD risk.

    Presence of subclinical coronary atherosclerosis by imaging or increased CAC score by CT is recommended as a risk modifier to improve risk classification for individuals at moderate risk or near treatment thresholds.

    In primary prevention, pharmacological LDL-C lowering therapy recommendations specified LDL-C thresholds for very high, high, moderate and low risk groups using explicit LDL-C values.

    Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited levels (>180 mg/dL) that confer lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia.

    onceLp(a) frequency
    5 yrsLipid panel interval
    ≥70 mg/dLLDL-C threshold (very high)
    127.9MUS people with CVD
    ≤1,000 pg/mLNT‑proBNP target HFrEF
    4–12 wksRecheck lipids after therapy change

    Coverage Criteria for Cardiovascular Risk Assessment Tests

    Lipid panel: Initial and monitoring criteria

    Covered when ANY of the following are met for lipid panel testing (simple lipid panel defined in Note 1):

    Lipid panel screening: Routine screening every 5 years for individuals ages 18 to 79 yearsage 18-79

    see Note 1 for simple lipid panel components

    Annual screening for increased CVD risk: Annual lipid panel for individuals at increased risk for cardiovascular disease as defined by the 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year ASCVD riskPCE-defined increased risk; PCE not calculated for individuals ≤39 years

    10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger

    Annual lipid panel for specified increased dyslipidemia risk conditions:
    Policy Summary
    PayerOscar Health
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy N/A
    Change TypeGuideline-driven substantive updates (SCORE2, CAC, Lp(a), LDL-C thresholds)
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionVerify member benefits before ordering tests and follow guideline-based indications for lipid panels, one-time Lp(a) measurement, and LDL-C–guided therapy decisions.
    SourceLink
    On This Page
    Coverage Criteria for Cardiovascular Risk Assessment TestsProcedure and Test CodingProvider Actions, Documentation, and AuthorizationBackground and ScopeDefinitions and Key TermsPolicy Revision History
    Annual lipid panel for individuals with obesity/metabolic syndrome, nephrotic syndrome, hypothyroidism, hyperthyroidism, pancreatitis, diabetes, chronic kidney disease, Cushing syndrome, pregnancy, cholestatic liver disease, lipid metabolism disorders, long-term drug therapy requiring lipid monitoring, family history of elevated lipids, premature heart disease, or history of stroke
    clinical diagnosis

    conditions listed in policy

    Monitoring on therapy or special populations: Lipid panel to establish baseline before initiating statin therapy; repeat every 4–12 weeks after initiation or change, then every 3–12 months as clinically indicated; for HIV patients starting ART: baseline, every 1–3 months after initiation/change, then every 6–12 months when stabletherapy initiation/change or ongoing therapy

    includes transplant patients and HIV-positive individuals

    ApoB and Lp(a) coverage

    Covered biomarkers and frequencies:

    Apolipoprotein B (apoB): Measurement of apoB (no more than once every 4 weeks) meets criteria for individuals with hypertriglyceridemia, diabetes mellitus, obesity/metabolic syndrome, other dyslipidemias (including very low LDL-C), individuals on lipid therapy, or suspected familial dysbetalipoproteinemia/familial combined hyperlipidemia≤ once every 4 weeks

    listed clinical indications; NLA supports role for apoB

    Lipoprotein(a) (Lp(a)): Measurement of Lp(a) once per lifetime (measurement when individual is ≥18 years) meets criteria to identify very high inherited levelsone lifetime measurement, age ≥18

    NLA/CCS/ESC recommend one-time measurement

    Not medically necessary / Not covered tests

    Not covered for CVD risk assessment:

    CRP/hs-CRP: Conventional or high-sensitivity C-reactive protein testing does not meet criteria for cardiovascular disease risk assessment

    DOES NOT MEET CRITERIA

    High-sensitivity cardiac troponin T (hs-cTnT): Measurement of hs-cTnT does not meet criteria for outpatient CVD risk assessment and stratification

    DOES NOT MEET CRITERIA

    Homocysteine testing does not meet criteria for CVD risk assessment, screening, evaluation, and management

    DOES NOT MEET CRITERIA; refer to other policies for non-CVD indications

    Novel lipid and non-lipid biomarkers: Measurements of novel biomarkers (e.g., apoA‑I, apoE, BNP/NT‑proBNP, cystatin C, fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase) do not meet criteria

    DOES NOT MEET CRITERIA

    Multi-biomarker CVD risk panels: CVD risk panels consisting of multiple individual biomarkers (other than simple lipid panels) do not meet criteria

    DOES NOT MEET CRITERIA; clinical utility lacking

    Long-chain omega-3 fatty acids measurement: Measurement of long-chain omega-3 fatty acids in red blood cell membranes does not meet criteria

    DOES NOT MEET CRITERIA

    Other tests: All other tests for assessing CVD risk do not meet criteria unless specifically listed as meeting criteria elsewhere in the policy

    policy: NOT covered unless specified

    Cardiovascular risk panels/profiles

    Proprietary cardiovascular risk panels and multi-marker profiles

    Proprietary panels: Commercial cardiovascular risk panels report combinations of lipids, inflammatory, genetic, and metabolic markers; clinical utility is lacking and the impact of results on patient management is unknown

    Examples include Genova Cardio Check™ and Cleveland HeartLab CVD Inflammation Testing Profile

    ACC/AHA guideline recommendations

    Guideline-based use of biomarkers to refine ASCVD risk assessment

    ACC/AHA risk assessment workflow: Adults 40–75 evaluated for CVD prevention should have 10‑year ASCVD risk estimation using PCEs and a clinician‑patient risk discussion; assessment of risk‑enhancing factors (family history, hs‑CRP, ABI, CAC) may be considered when treatment decisions are uncertainage 40–75 for PCE use

    CIMT not recommended routinely; contribution of some markers (ApoB, Lp(a), CKD, albuminuria, fitness) is uncertain

    Risk-enhancing biomarker cutoffs

    Specific biomarker thresholds considered risk-enhancing by guideline authors

    Biomarker risk-enhancing thresholds: Presence of any of the following may be considered risk‑enhancing: hs‑CRP ≥ 2 mg/L; persistently elevated triglycerides ≥ 175 mg/dL; Lp(a) ≥ 50 mg/dL (≥125 nmol/L); ApoB ≥ 130 mg/dL; ABI < 0.9see text

    ApoB measurement may be considered when triglycerides ≥ 200 mg/dL; Lp(a) relatively indicated with family history of premature ASCVD

    ADA guidance

    ADA recommendations relevant to testing and monitoring in diabetes

    ADA monitoring and screening: For people with diabetes: measure blood pressure at routine visits (or at least every 6 months); routine coronary artery disease screening in asymptomatic patients is not recommended; consider natriuretic peptide testing to facilitate prevention of heart failure and perform echocardiography if abnormal; obtain lipid profile at diagnosis and when initiating or changing statin therapy (repeat 4–12 weeks after initiation/change and annually thereafter)

    Children with T1D/T2D have specific lipid screening timing recommendations

    Recommended testing scenarios

    Coverage-relevant testing and monitoring described by guidelines (situations when measurement is recommended):

    Routine adult lipid screening interval: All adults: lipids evaluated at least every 5 years; adults at increased risk (diabetes, family history, premature heart disease, stroke) checked annuallyevery 5 years / annually for increased risk

    NLA and AACE/ACE recommendations

    Lipid testing around therapy changes: Obtain lipid profile at initiation of statin or other lipid‑lowering therapy, 4–12 weeks after initiation or dose change, and periodically thereafter (every 3–12 months or annually) to monitor response and adherence4–12 weeks; 3–12 months thereafter

    ADA, NLA, CMS guidance

    Lp(a) testing indications: Measure Lp(a) at least once in all adults to refine ASCVD risk; consider or recommend in patients with premature ASCVD, family history of premature ASCVD or elevated Lp(a), LDL‑C ≥190 mg/dL or suspected familial hypercholesterolemia, very high ASCVD risk, or when statin decision is uncertain in intermediate/borderline‑risk individualsone‑time measurement reasonable; repeat testing in specific situations (e.g., women after menopause, CKD, hypothyroidism)

    NLA and 2024 update support one‑time measurement

    ApoB and advanced lipoprotein testing: ApoB may be reasonable for initial evaluation and on therapy to assist diagnosis of familial dyslipidemias and to monitor treatment; consider advanced lipoprotein tests (ApoB, LDL‑P) in select patientsuse as complementary metric to LDL‑C; recommended timing mirrors LDL monitoring

    NLA supports role for ApoB

    hs‑CRP usage: High‑sensitivity CRP measured twice (optimally ~2 weeks apart) may be reasonable as an adjunct to major risk factors to further assess absolute risk in selected primary prevention patients with intermediate risk; not recommended for population screeningtwo measurements ~2 weeks apart

    CDC/AHA workshop recommendations

    Guideline-based consideration statements

    Guideline statements indicating when CVD risk assessment or BP screening may be considered

    CVD risk assessment by age: May be considered in the general population: men >40 years and women >50 years or postmenopausal with no known ASCVD risk factorsage >40 (men); age >50 or postmenopausal (women)

    ESC/EAS guideline phrasing 'may be considered'

    Opportunistic screening repeat interval: If CVD risk assessment is performed opportunistically, repetition of screening after 5 years may be considered (or sooner if risk was close to treatment thresholds)interval = 5 years or sooner if near treatment threshold

    Applies to opportunistic screening context

    Opportunistic BP screening in at‑risk adults: Opportunistic blood pressure screening is recommended for adults at risk for development of hypertension (examples include overweight individuals and those with a family history)risk group membership

    Recommendation context preserved from ESC/EAS excerpts

    Opportunistic screening

    Covered when ALL of the following are met according to ESC/EAS guidance excerpts:

    Opportunistic BP screening recommended: Adult patient is at risk for development of hypertension (examples include overweight or known family history of hypertension)

    Repeat screening after 5 years or sooner if risk close to treatment thresholds

    ESC/EAS 2025 focused update recommendations (primary prevention)

    Recommendations and decision rules from ESC/EAS 2025 focused update for primary prevention and lipid testing:

    Use SCORE2 for initial risk estimation: SCORE2 is recommended in apparently healthy people <70 years of age without established ASCVD, diabetes mellitus, chronic kidney disease, or genetic/rare lipid or blood pressure disorders to estimate 10‑year fatal and non‑fatal CVD riskage <70; absence of ASCVD/DM/CKD/genetic disorders

    Class I, Level B in guideline excerpts

    Risk modifiers to improve classification: Presence of subclinical coronary atherosclerosis by imaging or an increased CAC score by CT should be considered as risk modifiers in individuals at moderate risk or near treatment decision thresholds to improve risk classificationmoderate risk or near decision thresholds

    Class IIa, Level B

    Lp(a) screening: Consider one‑time measurement of Lp(a) in each adult to identify those with very high inherited Lp(a) (>180 mg/dL) who have lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia>180 mg/dL (>430 nmol/L)

    Screen at least once per adult lifetime

    LDL‑C thresholds for pharmacological therapy in primary prevention: Pharmacological LDL‑C‑lowering therapy is recommended or should be considered in primary prevention using explicit LDL‑C thresholds that vary by overall risk category (very high, high, moderate, low)see thresholds module for numeric cutpoints

    Use after optimizing non‑pharmacological measures

    ApoB usage: ApoB analysis is recommended for risk assessment particularly in people with high triglycerides, diabetes, obesity, metabolic syndrome, or very low LDL‑C and can be used as an alternative to LDL‑Cpresence of high TG/DM/obesity or very low LDL‑C

    Convenient and does not require fasting

    When testing or imaging is recommended

    Guideline-based recommendations and scenarios where testing or imaging may be considered

    Lp(a) measurement: Measure Lp(a) at least once in each adult to identify very high inherited levels (>180 mg/dL) associated with lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia>180 mg/dL (>430 nmol/L)

    CCS and ESC/EAS recommend a one‑time measurement for risk identification

    Use of ApoB/non‑HDL‑C: Recommend ApoB analysis or non‑HDL‑C as alternative/primary measurement for risk assessment in people with high triglycerides, diabetes, obesity, or very low LDL‑C; prefer non‑HDL‑C or ApoB when TG ≥ 1.5 mmol/LTG ≥ 1.5 mmol/L; non‑HDL‑C < 2.6 mM or apoB < 0.8 g/L as treatment targets per CCS

    ApoB convenient and not fasting‑dependent; preferred in certain metabolic states

    CAC and vascular imaging: Consider CAC scoring by CT or arterial plaque assessment (carotid/femoral ultrasound) to assist treatment decisions in patients at moderate/intermediate ASCVD risk or when LDL‑C goals are not achieved with lifestyle measuresintermediate risk (example: FRS 10%–20%)

    Several societies endorse CAC for reclassification; some recommend against routine use in high‑ or low‑risk groups

    Routine circulating biomarkers: Routine assessment of novel circulating biomarkers (e.g., hs‑CRP, certain apolipoproteins) is generally not recommended for CVD risk stratification due to limited additional value

    ESC, EASD, Endocrine Society and others note limited incremental value

    Screening intervals: Repeat global risk assessment approximately every 5 years for adults; lipid levels may be measured every 5 years in asymptomatic adults with shorter intervals for higher‑risk personsevery 5 years standard; more often if higher risk

    Multiple guidelines indicate five‑year intervals

    Not routinely recommended

    Guidance recommending against routine testing

    Routine CAC/biomarker testing discouraged: Do not routinely order CAC or additional biomarkers for all patients; use selectively for intermediate‑risk patients or where results will change management

    VA/DoD and other bodies suggest against routine use; USPSTF finds insufficient evidence to add ABI, hs‑CRP, or CAC to traditional risk assessment in asymptomatic adults

    Expanded lipid panels discouraged: Routine ordering of expanded lipid panels (e.g., particle sizing, NMR) for population screening is discouraged

    ASCP and other organizations discourage routine expanded lipid testing

    The policy lists multiple individual biomarkers and multi-analyte panels that DO NOT MEET CRITERIA for cardiovascular disease risk assessment. Examples explicitly named include conventional or high-sensitivity CRP, high-sensitivity cardiac troponin T (hs-cTnT), homocysteine, cystatin C, BNP/NT‑proBNP, apolipoproteins (eg, apoAI), fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase, and long-chain omega‑3 fatty acid measurement in red blood cell membranes. The policy further states that proprietary multi‑biomarker CVD risk panels (combinations of these markers reported together) also DO NOT MEET CRITERIA because their clinical utility and impact on patient management are lacking.

    The document notes that Cystatin C has been proposed as a marker related to inflammation and obesity and as an indicator of impaired kidney function, which is itself a CVD risk factor. However, it states there is no published literature proving Cystatin C’s effectiveness for predicting cardiovascular risk in the excerpts provided and that Cystatin C is not routinely used as a CVD biomarker.

    Commercial cardiovascular risk panels that combine multiple lipids, inflammatory, genetic, and metabolic markers are discussed but the policy makes clear the clinical utility is lacking. The policy explains that these panels report multiple individual tests and/or use proprietary algorithms, yet their impact on clinical management is unknown and therefore they are not supported as routine tools for CVD risk assessment.

    Guidance cited in the policy emphasizes that hs‑CRP may be measured as an adjunct in selected, metabolically stable patients (optimally measured twice about two weeks apart) but the CDC/AHA recommends against screening the entire adult population for hs‑CRP as a public health measure. Consistent with that position, the policy states CRP (conventional or high‑sensitivity) DOES NOT MEET CRITERIA for routine CVD risk assessment.

    Some guideline excerpts included in the policy do not contain explicit exclusions within those particular sections. The policy preserves the original guideline language in these excerpts and does not add additional coverage exclusions beyond those stated elsewhere in the document.

    Other extracted guideline passages likewise do not include explicit coverage exclusions in the text fragments shown. These excerpts focus on recommendations for opportunistic screening intervals and risk‑assessment contexts rather than listing specific tests as excluded.

    The ESC/EAS guidance quoted in the policy specifically notes that routine measurement of Apo C‑III is not recommended because its clinical utility is unknown; the guideline therefore recommends against routine Apo C‑III testing for risk assessment.

    Guideline text describes the role and limits of coronary artery calcium (CAC) scoring: CAC can be helpful as a risk modifier to improve classification for individuals at moderate risk or near treatment thresholds, but several societies (eg, CCS) recommend that CAC screening not be undertaken for high‑risk individuals, patients already on statin therapy, or most asymptomatic low‑risk adults. Thus CAC is presented as a selective reclassification tool rather than a general screening test.

    The policy includes a regulatory note about laboratory‑developed tests (LDTs): many LDTs are developed and validated in‑house and are regulated by CMS under CLIA as high‑complexity tests. LDTs are not FDA‑approved or cleared, and while FDA clearance is not required for clinical use, this regulatory status is noted in the document.

    Certain extracted reference sections in the document contain only bibliographic entries or publication history and do not include explicit coverage criteria, medical‑necessity statements, or exclusions within those particular chunks.

    In addition to the individual markers already named, the policy excerpt lists other biomarkers and assays discussed in the evidence and commercial panels, including myeloperoxidase, Lp‑PLA2, oxidized LDL, ADMA/SDMA, microalbumin, and multi‑component proprietary tests. The policy treats these additional biomarkers as part of the broader group of novel or multi‑marker tests that generally DO NOT MEET CRITERIA for routine CVD risk assessment unless specifically covered elsewhere.

    The policy references meta‑analysis data on isotretinoin indicating that although isotretinoin can change mean laboratory values (including lipid measures) in treated patients, the proportion of patients with clinically meaningful abnormalities was low, and the authors concluded these data do not support routine monthly laboratory testing for standard acne dosing. The excerpt is cited to explain monitoring context rather than to endorse routine CVD biomarker testing.

    The document states that elevated homocysteine has been associated with increased CVD risk but also notes that clinical trials lowering homocysteine have not demonstrated clear reductions in cardiovascular events. Consequently, routine measurement of homocysteine for CVD risk assessment is not consistently recommended and is considered of unproven clinical utility in this context.

    The CDC/AHA workshop cited in the policy concluded that hs‑CRP measurement may be reasonable as an adjunct in selected, metabolically stable patients (optimally measured twice about two weeks apart), but it recommended against population‑wide screening for hs‑CRP. The policy mirrors that stance by not supporting hs‑CRP as a routine screening test for all adults.

    The extracted evidence reference list and publication history sections do not contain statements classifying tests as not medically necessary; they serve as supporting citations and record governance approval of the document on 06/16/2026.

    Other scattered evidence or reference excerpts included in the document do not contain explicit not‑medically‑necessary (NMN) determinations within those chunks; the policy’s NMN conclusions are stated in the coverage and exclusions sections elsewhere in the document.

    The policy references the 2021 ESC guidance noting that C‑reactive protein provides limited additional value and that Lp(a) has limited reclassification potential in some contexts. The document therefore reflects that routine use of CRP or broad novel biomarkers adds only limited incremental predictive value and should be used selectively.

    Consistent with multiple guideline statements included in the policy, routine assessment of novel circulating or urinary biomarkers for CVD risk stratification is not recommended because they generally provide limited additional clinical value and have not been shown to change management or outcomes in most asymptomatic individuals.

    Several extracted chunks do not contain determinations about not‑medically‑necessary status; where NMN conclusions are intended, they are stated explicitly in the policy coverage, exclusion, and not‑medically‑necessary sections rather than in reference or evidence list fragments.

    Procedure and Test Coding

    Covered CPT Codes (listed)CPT
    80061Lipid panel
    81599Unlisted multianalyte assay with algorithmic analysis
    82172Apolipoprotein, each
    82465Cholesterol, serum or whole blood, total
    82610Cystatin C
    83090Homocysteine
    83695Lipoprotein (a)
    83718Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
    83721Lipoprotein, direct measurement; LDL cholesterol
    83722Lipoprotein, direct measurement; small dense LDL cholesterol
    1–10 of 12
    1/2
    Additional CPT/HCPCS and Proprietary CodesCPT | Proprietary
    84478Triglycerides
    84484Troponin, quantitative
    84512Troponin, Qualitative
    84999Unlisted chemistry procedure
    85384Fibrinogen; activity
    85415Fibrinolytic factors and inhibitors; plasminogen activator
    86140C-reactive protein
    0019MLipoprotein, blood, high resolution fractionation and quantitation (proprietary VAP test)
    Proprietary tests mentionedmixed
    SOMAmer (proprietary)Cardiovascular disease protein biomarker aptamer-based panel (SomaLogic) — proprietary test referenced
    VAP Cholesterol Test (proprietary)Vertical auto profile ultracentrifugation proprietary test (VAP Diagnostics)
    Liposcale (proprietary)NMR-based lipoprotein profile (CIMA Sciences)
    SmartHealth Vascular Dx (proprietary)Proprietary multi-marker immunoassay with algorithm (Morningstar Laboratories)
    HDL Reverse Cholesterol Transport Panel (proprietary)Quest Diagnostics proprietary test reporting pCAD score
    Persistently elevated triglycerides — threshold
    Persistently elevated triglycerides≥ 175 mg/dL
    Context / noteListed as a risk‑enhancing lipid criterion by ACC/AHA guidance
    Measurement implicationConsider as persistent primary hypertriglyceridemia when evaluating ASCVD risk
    Elevated hs-CRP — threshold and notes
    Elevated hs-CRP≥ 2.0 mg/L
    Assay noteHigh-sensitivity assays detect CRP down to ~0.3 mg/L for cardiovascular risk assessment
    Measurement recommendationCDC/AHA: measure hs-CRP twice ~2 weeks apart when used as adjunct
    Elevated apoB — threshold
    Elevated apoB≥ 130 mg/dL
    Corresponding LDL-CApoB ≥130 mg/dL corresponds roughly to LDL-C ≥160 mg/dL
    IndicationConsider ApoB measurement when triglycerides ≥200 mg/dL or in select metabolic conditions
    Lp(a) elevated threshold
    Lp(a) elevated threshold≥ 50 mg/dL or ≥ 125 nmol/L
    ContextRelative indication for measurement when family history of premature ASCVD present
    Risk implicationConsidered a risk-enhancing factor by ACC/AHA
    Lipoprotein(a) 90th percentile — informational
    Estimated 90th percentile for Lp(a)≈ 39 mg/dL
    Method notePopulation estimate; serum Lp(a) highly genetically determined
    Interpretation90th percentile ~39 mg/dL is below risk-enhancing cutoffs used clinically
    Lp(a) baseline and on-statin risk thresholds
    Baseline Lp(a) risk thresholdBaseline ≥ 30 mg/dL (HR 1.13–1.36)
    On‑statin Lp(a) risk thresholdOn‑statin ≥ 50 mg/dL (HR 1.08–1.42)
    Study sourceWilleit et al. pooled analysis (n≈26,069) linking these thresholds to incremental ASCVD risk
    NT-proBNP prognostic threshold in HFrEF
    NT-proBNP prognostic threshold in HFrEF≤ 1,000 pg/mL
    Clinical implicationNT-proBNP ≤1,000 pg/mL during guideline therapy associated with better outcomes in HFrEF
    Study noteGUIDE-IT trial analysis cited for prognostic association
    Guideline biomarker thresholds — examples
    Example guideline biomarker cutpointshs-CRP ≥2 mg/L; TG ≥175 mg/dL; Lp(a) ≥50 mg/dL (≥125 nmol/L); ApoB ≥130 mg/dL; ABI <0.9
    UseListed as risk-enhancing factors to refine ASCVD risk after quantitative assessment
    Measurement contextApoB measurement suggested when TG elevated; Lp(a) relatively indicated with family history
    Troponin quartile thresholds — example study cutoffs
    Troponin quartile example cutoffs (study)Highest quartile ≥ 5.2 ng/L vs lowest quartile ≤ 3.1 ng/L
    Study contextFord et al. 2016 cohort study linking higher troponin quartile to increased CVD risk
    ImplicationElevated high-sensitivity troponin may predict long-term risk but not recommended routinely for outpatient ASCVD screening
    Lipid measurement timing thresholds
    Timing after therapy initiation/intensificationMeasure LDL-C 4 to 6 weeks after initiation or intensification of lipid-lowering therapy
    Follow-up for stable regimensLipid measurements recommended 3–12 months for those on a stable medication regimen (NLA)
    ApoB noteApoB measurement is convenient and does not require fasting; timing mirrors LDL monitoring recommendations
    Actionable lipid thresholds
    Actionable LDL-C thresholdsLDL-C ≥190 mg/dL (adults) or ≥160 mg/dL (children)
    Actionable triglyceride thresholdTG ≥500 mg/dL (report as severe hypertriglyceridemia requiring action)
    Reporting expectationLaboratory reports should denote these extremely elevated values to flag possible familial or severe disorders
    Age thresholds mentioned for population screening
    Age threshold — menMen >40 years
    Age threshold — womenWomen >50 years or postmenopausal
    ContextESC/EAS suggest systematic or opportunistic risk assessment in these age groups; repeat screening interval often 5 years
    Age thresholds — men/women repeated
    Men age cutpoint>40 years
    Women age cutpoint>50 years or postmenopausal
    Recommendation contextApplies to consideration of systematic or opportunistic CVD risk assessment per ESC/EAS
    Repeat interval for opportunistic screening
    Repeat interval for opportunistic screeningRepeat screening after 5 years (or sooner if risk near treatment thresholds)
    ApplicabilityESC/EAS: applies to opportunistic CVD risk assessment context
    ExceptionRepeat sooner when risk close to treatment decision thresholds
    Repeat screening interval — reiterated
    Standard repeat screening interval5 years (or sooner if risk near treatment thresholds)
    Guideline sourceESC/EAS recommendations for opportunistic screening
    NoteHigher‑risk individuals may require more frequent reassessment
    LDL-C thresholds — therapy recommendation and consideration cutpoints
    LDL-C threshold to recommend therapy (very high risk)≥1.8 mmol/L (70 mg/dL)
    LDL-C threshold to consider therapy (very high risk)≥1.4 mmol/L (55 mg/dL) but <1.8 mmol/L (70 mg/dL)
    Other risk categoriesHigh risk recommend at ≥2.6 mmol/L (100 mg/dL); moderate/low risk thresholds also specified by guideline
    Lp(a) threshold — very high level
    Very high Lp(a) numeric threshold>180 mg/dL (>430 nmol/L)
    Clinical significanceAssociated with lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia
    Measurement recommendationConsider one-time measurement in adults to identify very high inherited levels
    Very high Lp(a) — repeated threshold
    Very high Lp(a)>180 mg/dL (>430 nmol/L)
    Guideline actionIdentify individuals with inherited very high Lp(a) for lifetime risk assessment
    RecommendationMeasure at least once during adulthood
    non-HDL-C and ApoB treatment targets (CCS suggestion)
    non-HDL-C and ApoB treatment targets (CCS suggestion)non-HDL-C < 2.6 mM or apoB < 0.8 g/L
    When preferredPrefer non-HDL-C or ApoB over LDL-C when triglycerides ≥1.5 mmol/L
    Use caseTargets suggested for intermediate/high risk decision-making per CCS guidance
    Triglyceride threshold — prefer non-HDL-C/ApoB
    Triglyceride threshold to prefer non-HDL-C/ApoBTG ≥ 1.5 mmol/L
    ImplicationUse non-HDL-C or ApoB rather than LDL-C for interpretation and targets when TG above this cutpoint
    SourceCanadian Cardiovascular Society guidance

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Verify member benefits before ordering tests

    Application of the policy criteria depends on the member's benefit coverage at the time of the request; Medicare and Medicaid specifications are found in the ‘Applicable State and Federal Regulations’ section and must be followed when applicable.

    • Verify member benefits and any applicable government coverage (LCDs/NCDs or state Medicaid rules) before ordering tests.
    Note

    No prior authorization specified in excerpt

    The excerpted policy does not specify any prior authorization requirements for the tests and biomarker measurements described.

    Note

    PA not specified for guideline-recommended biomarkers

    No prior authorization requirements for biomarker testing are stated in the guideline excerpts; guideline language focuses on when measurements are recommended rather than payer PA rules.

    Note

    No PA requirements in guideline excerpts

    The guideline excerpts do not state any prior authorization requirements for lipid or biomarker testing.

    Note

    No PA requirements in this excerpt

    No prior authorization requirements are stated in the provided excerpt of this policy.

    Note

    PA not specified for these sections

    This document excerpt does not specify prior authorization requirements for the listed cardiovascular risk assessments or tests.

    Note

    No PA requirements stated

    No prior authorization requirements are described in the provided excerpts for the tests and biomarkers discussed.

    Step Therapy

    Follow guideline LDL‑C thresholds for therapy decisions

    The ESC/EAS guideline specifies LDL-C thresholds by risk category for considering or recommending pharmacological LDL-C–lowering therapy (examples: very high risk recommend therapy at LDL-C ≥1.8 mmol/L [70 mg/dL]; consider therapy at ≥1.4 mmol/L [55 mg/dL] for very high risk; high risk recommend at ≥2.6 mmol/L [100 mg/dL]; see guideline thresholds for full numeric cutpoints).

    • Use the guideline numeric LDL‑C cutpoints by overall risk category when discussing pharmacologic therapy decisions.
    • Apply thresholds only after optimizing non‑pharmacological measures, per guideline text.
    Prior Authorization

    Follow applicable government coverage determinations

    If there is a conflict between this policy and an applicable government coverage determination (e.g., Medicare LCD/NCD or state Medicaid), the government policy governs the determination; providers must follow those rules for authorization and coverage decisions.

    • Check the Medicare Coverage Database and relevant state Medicaid resources for current government policy when applicable.
    Prior Authorization

    Verify PA requirements for listed procedure and proprietary codes

    The policy lists CPT/HCPCS and proprietary procedure codes (examples: 80061, 82172, 83695, 84478, 86140, 0019M and various proprietary panel identifiers). Providers should verify any payer-specific prior authorization requirements for these codes before ordering.

    • Confirm PA requirements for listed CPT/HCPCS and proprietary test codes in the payer's authorization system prior to submission.
    Note

    No PA requirements in this section

    No prior authorization requirements are specified in this section of the excerpted policy.

    Note

    No action specified in excerpt

    (No specific provider action stated in the excerpted inventory placeholder.)

    Step Therapy

    No step therapy sequences specified

    No step‑therapy sequences or mandated therapeutic sequencing are specified in the provided excerpts.

    Step Therapy

    No mandated step‑therapy for biomarkers

    Guideline excerpts describe use of additional biomarkers to inform treatment decisions after traditional risk estimation and clinician–patient discussion, but do not mandate step‑therapy sequences.

    Step Therapy

    No step therapy requirements in guideline excerpts

    No step‑therapy rules are specified in the guideline excerpts provided.

    Step Therapy

    No step therapy described in this excerpt

    The provided excerpts do not describe step‑therapy requirements for biomarker testing or imaging.

    Step Therapy

    No step therapy requirements present

    No step‑therapy requirements for testing are specified in these excerpts of the policy.

    Step Therapy

    Step therapy not specified

    No step‑therapy sequences are specified in the policy excerpts for the tests and biomarkers discussed.

    Step Therapy

    Initiate pharmacologic therapy after optimizing lifestyle measures

    Pharmacological LDL‑C‑lowering therapy recommendations in the guideline apply after optimization of non‑pharmacological measures; providers should document attempts at lifestyle modification prior to initiating therapy when appropriate.

    • Ensure non‑pharmacological measures have been optimized before initiating pharmacological LDL‑C lowering per guideline language.
    Step Therapy

    Consider CAC to guide lipid‑lowering therapy in intermediate‑risk patients

    Consider coronary artery calcium (CAC) scoring by CT to help reclassify risk and inform initiation or intensification of lipid‑lowering therapy in patients at intermediate or moderate ASCVD risk when treatment decisions are uncertain.

    • Do not use CAC routinely in high‑risk patients, patients already on statin therapy, or most low‑risk asymptomatic adults per guideline/CCS recommendations.
    Note

    No action specified

    (Inventory placeholder; no action specified in extracted text.)

    Step Therapy

    No step therapy rules in extracted chunks

    (No step‑therapy rules are present in these extracted chunks.)

    Documentation Required

    Document services and code claims accurately

    Providers must submit accurate documentation of services performed and code claims appropriately according to industry-standard coding guidelines; failure to follow coding/billing guidelines or to provide sufficient documentation may result in claim denial or recoupment.

    • Document clinical indication, test ordered, laboratory results, and rationale for testing in the medical record to support medical necessity.
    • Code claims according to CPT/HCPCS and payer-specific guidance and verify coding before submission.
    Documentation Required

    Record evidence-based rationale for monitoring

    The document summarizes clinical trial and meta‑analysis contexts relevant to monitoring (e.g., statin response variability and isotretinoin lipid changes) that support the need for monitoring in specific therapies; include monitoring rationale in documentation when ordering tests.

    • When ordering monitoring based on drug therapy (e.g., statins, isotretinoin), document the therapy and clinical reason for testing in the chart.
    Documentation Required

    Obtain baseline and 4–12 week lipid monitoring after statin start

    When initiating statin therapy obtain a baseline fasting lipid panel and repeat testing 4–12 weeks after initiation or dose change to assess adherence and response; thereafter repeat measurements every 3–12 months as clinically indicated.

    • Document baseline and follow‑up lipid results and any medication changes to support medical necessity of subsequent tests.
    Documentation Required

    Ensure laboratory reports flag extreme/ actionable lipid values

    Laboratory reports should denote desirable values and specifically identify extremely elevated LDL‑C (≥190 mg/dL in adults or ≥160 mg/dL in children) and actionable abnormalities such as fasting triglycerides ≥500 mg/dL; CDC Lipids Standardization Program certification may be used to demonstrate laboratory accuracy.

    • Ensure lab reports highlight LDL‑C and TG thresholds and include method and fasting status where relevant.
    Note
    Note
    Note
    Documentation Required

    Timing: measure LDL‑C 4–6 weeks after therapy initiation/intensification

    Measure LDL‑C 4 to 6 weeks after initiation or intensification of lipid‑lowering therapy per ESC/EAS guidance; ApoB and ApoA‑I measurements are convenient and do not require fasting and may be used as alternatives per guideline text.

    • Use ApoB/ApoA‑I as an alternative when triglycerides are high or fasting not feasible.
    Documentation Required

    Obtain baseline lipid profile and population‑specific follow‑up tests

    Obtain a baseline lipid profile (TC, HDL, non‑HDL, triglycerides) prior to treatment; for some populations (e.g., renal transplant patients) measure TC, HDL and LDL after 3 months of therapy and monitor transaminases at baseline, 3 months, and 12 months where indicated.

    • Record baseline transaminases where statin initiation is planned in transplant patients and follow the specified follow‑up intervals.
    Documentation Required

    Align documentation and coverage decisions with government policies

    Providers should reference and follow applicable Medicare/Medicaid LCDs/NCDs and state Medicaid policies when they differ from this policy; documentation should support alignment with those government policies.

    • Check the Medicare Coverage Database and relevant state Medicaid resources for current determinations prior to ordering when government coverage applies.
    Note
    Denial Risk

    Claims may be denied if coding or documentation is insufficient

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed and documentation is insufficient to support medical necessity.

    • Ensure clinical documentation includes diagnosis, indication for test, therapy status, and follow‑up plan to substantiate medical necessity.
    Note
    Denial Risk

    Proprietary cardiovascular risk panels risk denial without demonstrated utility

    Commercial proprietary multi‑marker cardiovascular risk panels lack demonstrated clinical utility and their impact on patient management is unknown; tests reported as panels may be discouraged for coverage and risk denial if clinical utility is not shown.

    • Provide clear clinical rationale and supporting documentation if ordering proprietary panels; expect potential denial when clinical utility is not documented.
    Denial Risk

    Document rationale for frequent lipid monitoring to avoid denial

    CMS guidance allows more frequent lipid testing (up to six times in the first year) when monitoring long‑term anti‑lipid therapy; if monitoring frequency outside standard intervals is claimed, document the clinical rationale to avoid denial.

    • Document reasons for increased monitoring frequency (e.g., marked lipid elevations, therapy changes, inadequate response) to support medical necessity.
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Background and Scope

    Background: The policy frames cardiovascular risk assessment around the use of standard lipid panels and selective biomarkers to estimate a person’s risk of CVD events and to guide clinical decision‑making. It notes that traditional risk algorithms may miss a proportion of events and that biomarkers and imaging can be used selectively as risk modifiers, but many novel tests show only modest incremental predictive ability.

    Definitions and Key Terms

    Pooled Cohort Equations (PCEs) — definition & variables
    DefinitionPooled Cohort Equations (PCEs) estimate 10‑year ASCVD risk using age, sex, race, total cholesterol, HDL‑C, LDL‑C, systolic BP, treatment for hypertension, diabetes, and smoking status
    UseRecommended for 10‑year risk estimation to inform clinician‑patient risk discussion and treatment decisions
    LimitationPCEs have limitations when applied to individuals; additional risk‑enhancing factors may refine risk
    Lipoprotein(a) — definition & indications
    DefinitionLipoprotein(a) is an LDL-like particle with atherogenic potential whose serum levels are highly genetically determined
    When to measureMeasure once in adulthood to identify very high inherited levels (>180 mg/dL) and consider when family history of premature ASCVD or unexplained premature disease
    Risk-enhancing cutoff≥50 mg/dL (≥125 nmol/L) considered risk-enhancing in guidelines
    Apolipoprotein B (ApoB) — definition
    DefinitionApolipoprotein B (ApoB) is the primary structural protein of LDL and VLDL; one ApoB‑100 molecule per LDL particle reflects particle number
    Clinical roleApoB is recommended as an alternative primary measurement for screening/management, especially with high TG, diabetes, obesity, or very low LDL‑C
    Threshold noteApoB ≥130 mg/dL is listed as a risk‑enhancing cutoff in guidelines
    Apolipoprotein A-I (Apo A-I) — definition
    DefinitionApolipoprotein A‑I (Apo A‑I) is the main structural protein of HDL and is measured directly or as an ApoB:ApoA‑I ratio to reflect lipoprotein balance
    UseMay be used as an alternative marker for cardiovascular risk; measurement is convenient and not fasting‑dependent
    Clinical noteApo A‑I often reported with ApoB to provide atherogenic:antiatherogenic ratio
    Lipoprotein(a) (Lp[a]) — definition & genetics
    DefinitionLipoprotein(a) (Lp[a]) is an LDL-like particle with atherogenic potential and serum levels are highly genetically determined
    Clinical implicationsElevated Lp(a) modestly increases CAD risk and very high levels (>180 mg/dL) confer lifetime risk similar to HeFH
    Measurement method noteDensity gradient ultracentrifugation is standard; ELISA techniques may be affected by apo(a) isoforms
    BNP / NT-proBNP — definition & context
    DefinitionBNP/NT‑proBNP are ventricular hormones that rise with cardiac pressure/volume overload and are established diagnostic/prognostic markers for heart failure
    Clinical threshold noteNT‑proBNP ≤1,000 pg/mL during guideline therapy associated with better outcomes in HFrEF
    Use caseMay be used to facilitate prevention of heart failure and to guide further testing when abnormal
    C-reactive Protein (CRP) / hs-CRP — definition & predictive role
    DefinitionC-reactive protein (CRP) is an inflammatory marker measurable by high-sensitivity assays (hs‑CRP) to detect low-range inflammation predictive of CVD events
    Assay capabilityhs‑CRP assays detect concentrations down to ~0.3 mg/L and are useful for assessing residual inflammatory risk
    Guideline rolehs‑CRP ≥2 mg/L listed as risk‑enhancing; CDC/AHA recommend measuring twice ~2 weeks apart when used as adjunct
    hs-CRP — high-sensitivity assay definition & use
    High-sensitivity assay definitionhs‑CRP assays detect CRP down to ~0.3 mg/L and can quantify levels in asymptomatic patients (<3 mg/L)
    Clinical useMay be reasonable as an adjunct to major risk factors for intermediate‑risk patients; not recommended for population screening
    Measurement recommendationCDC/AHA: two measurements ~2 weeks apart when used clinically
    Remnant cholesterol / IDL — definition
    DefinitionRemnant cholesterol/IDL represents cholesterol content of triglyceride‑rich lipoproteins (VLDL/IDL and chylomicron remnants) and is proatherogenic
    EstimationCan be approximated from triglyceride levels or non‑HDL‑C when advanced testing not available
    Clinical implicationElevated nonfasting TG associated with increased CVD risk via remnant cholesterol
    Lp-PLA2 — definition & evidence
    DefinitionLp‑PLA2 is an inflammatory enzyme expressed in atherosclerotic plaques proposed as a vascular biomarker
    Evidence noteStudies show Lp‑PLA2 is an independent predictor in some cohorts but inhibitor trials have not shown outcome benefit
    Clinical utilityMay have limited predictive value in asymptomatic populations; utility greater in selected symptomatic/metabolic patients
    Extremely elevated LDL-C — definition
    Extremely elevated LDL‑C thresholdLDL‑C ≥190 mg/dL in adults (≥160 mg/dL in children)
    ActionShould be reported as possible familial hypercholesterolemia or severe hypercholesterolemia
    Reporting guidanceLaboratories expected to flag these values for clinician attention
    hs-CRP usage — measurement recommendation
    hs-CRP measurement recommendationMeasure hs‑CRP twice (optimally ~2 weeks apart) when used as an adjunct to major risk factors
    Population screening stanceCDC/AHA recommend against screening the entire adult population for hs‑CRP
    Clinical follow-upIf abnormal, repeat testing and evaluate for noncardiac sources of inflammation before clinical interpretation
    Lp(a) measurement recommended by AACE — when indicated
    AACE recommendation for Lp(a)Measure Lp(a) in settings of family history of premature ASCVD and in patients with premature or recurrent ASCVD despite LDL‑C lowering
    UtilityUsed to refine risk in selected patients rather than population screening
    Age noteMeasure when individual is ≥18 years if indicated
    PCE ASCVD Risk Calculator — purpose
    PCE ASCVD Risk CalculatorEstimates 10‑year and lifetime ASCVD risk using demographic and clinical lipid/BP/smoking/diabetes variables
    RolePrimary tool for initial quantitative risk estimation to guide prevention discussions
    LimitationCannot calculate 10‑year risk for individuals ≤39 years and may under/overestimate individual risk
    Opportunistic screening — definition
    Opportunistic screening definitionScreening performed during routine healthcare encounters for individuals not enrolled in organized screening programs
    ApplicationUsed for opportunistic BP checks and CVD risk assessment in at‑risk adults
    Repeat intervalIf performed opportunistically, repeat after ~5 years (or sooner if near treatment thresholds)
    Opportunistic BP screening — definition & context
    Opportunistic BP screening definitionBlood pressure measurement offered during routine encounters to adults at increased risk for hypertension (e.g., overweight, family history)
    Recommendation contextESC/EAS supports opportunistic BP screening in at‑risk adults to identify hypertension early
    Repeat intervalRepeat opportunistic screening after 5 years or sooner when risk near treatment thresholds
    Repeat screening interval — general recommendation
    Repeat screening interval (general guidance)Reassessment after five years is suggested (or sooner if risk is near treatment thresholds)
    ScopeApplies to global CVD risk assessment and opportunistic screening contexts per ESC/EAS guidance
    ExceptionHigher‑risk individuals should have more frequent reassessment
    SCORE2 — recommended 10-year CVD risk tool
    SCORE2 definitionSCORE2 is a 10‑year CVD risk tool recommended for apparently healthy people <70 years without established ASCVD, diabetes, CKD, or genetic/rare lipid or BP disorders
    Use caseRecommended by ESC/EAS 2025 focused update for initial risk estimation in primary prevention
    PopulationDesigned for European populations; replacement for older SCORE guidance
    Lp(a) >180 mg/dL — definition of very high level
    Lp(a) very high level definition>180 mg/dL (>430 nmol/L)
    Clinical equivalenceAssociated lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia
    Measurement recommendationConsider one-time measurement in adults to identify these very high inherited levels
    Lp(a) — recommendation to measure at least once
    Measure Lp(a) at least onceRecommendation to measure Lp(a) at least once in adults to identify very high inherited levels
    ContextSeveral societies (ESC/EAS, CCS, NLA) support one‑time lifetime measurement for risk identification
    Not a routine repeat testRepeat measures generally not indicated unless specific clinical situations arise
    ApoB — recommended alternative primary measurement
    ApoB recommendationApoB recommended as an alternative primary measurement for screening and management, particularly when triglycerides are high or LDL‑C very low
    AdvantagesConvenient, accurate, does not require fasting and is less affected by TG levels
    Clinical scenariosUse in diabetes, obesity, metabolic syndrome, and select patients to guide therapy
    CAC — definition & role in reclassification
    CAC definition & useCoronary artery calcium (CAC) score by CT quantifies coronary atherosclerosis and may reclassify risk in intermediate‑risk individuals
    Clinical roleConsidered a risk modifier to guide initiation/intensification of lipid‑lowering therapy when treatment decisions are uncertain
    LimitationsNot recommended routinely for high‑risk or most low‑risk patients per CCS guidance
    Laboratory-developed test (LDT) — definition & regulatory note
    LDT definitionLaboratory‑developed test (LDT) is a test developed and performed within a single laboratory and regulated by CMS as high‑complexity under CLIA '88
    Regulatory noteLDTs are not FDA‑approved or cleared; FDA clearance/approval not currently required for clinical use
    ImplicationLDT status may affect assay harmonization and interpretation of some proprietary biomarker tests
    Misc referenced biomarkers and interventions
    Misc referenced biomarkers & interventionsAdditional biomarkers referenced include Lp‑PLA2, high‑sensitivity cardiac troponin, omega‑3 fatty acids, apolipoproteins, and advanced lipid measures
    Evidence noteNumerous primary studies and guideline documents cited; clinical utility varies and many lack outcome‑changing evidence
    Policy stanceRoutine use of many novel circulating biomarkers and proprietary multi‑marker panels is not recommended due to limited clinical value

    Policy Revision History

    2026-10-01policy_effectiveLatest

    Policy effective date set to 2026-10-01.

    2026-06-16last_review_governance_approval

    Last review and governance approval recorded on 2026-06-16.

    2025-06-16guideline_update_incorporated

    ESC/EAS 2025 focused update recommendations (use of SCORE2, CAC as risk modifier, LDL‑C cutpoints, and one-time Lp(a) screening) were added to guideline-based considerations included in the policy.

    2024-08-01evidence_update

    National Lipid Association (NLA) / related expert consensus evidence (ApoB guidance and Lp(a) measurement recommendations) from 2024 were incorporated into coverage rationale and testing frequency statements.

    Publication and change history: this policy’s publication history notes governance approval on 06/16/2026 and the evidence/reference sections cited in the document provide the supporting literature behind the policy statements and coverage determinations.